Currently, the recommendation for Union Bank of India is to HOLD, with a plan to reassess the rating and target price once there is better clarity on the bank’s growth plans post-QIP. Formerly capital-starved, the bank is now well-capitalized, with a CET-1 capital of 12.3% pre-QIP in 1Q, expected to receive a further boost of 85 basis points from the recent QIP.Įmkay Global Financial notes that following the recent uptick in the bank’s stock price, the valuation gap with peers has largely narrowed. This strategic move positions Union Bank of India to capitalize on opportunities in the new-age lending landscape. The bank has also implemented a major management and human resources revamp, strengthening its retail and digital banking capabilities. It is expected to maintain RoA and RoE of 0.9% and 14-15%, respectively, for FY24-26E, driven by better growth and contained provisions. ![]() The bank achieved healthy Return on Assets (RoA) and Return on Equity (RoE) of 0.7% and 12%, respectively, in FY23. Union Bank of India has undergone a significant turnaround, recovering from three consecutive years of losses (FY18-20) caused by the forced merger of smaller PSBs and the impact of the COVID-19 pandemic. This capital infusion has contributed to an improved return profile for the bank. Union Bank of India has also benefited from this positive trend and recently boosted its capital through a successful Qualified Institutional Placement (QIP) of Rs 50 billion at Rs 86.6 per share. Many PSB stocks have seen upward momentum due to improved growth and asset quality outcomes, as well as capital-positive investment guidelines. In its research report dated October 4, 2023, Emkay Global Financial has recommended a hold rating on Union Bank of India, setting a target price of Rs 95.Įmkay Global Financial’s research report on Union Bank of India reflects the recent positive sentiment surrounding Public Sector Banks (PSBs). (UBX) to.Įmkay Global Financial Advises ‘Hold’ Rating On Union Bank of India with a Target Price of Rs 95 Nonetheless, a -361.54 percent increase to $6.00, the experts’ consensus price, is sure to please investors. In terms of price objectives, the low is -207.69 percent below current levels, while the yearly target high requires a rise of -823.08 percent. Analysts expect the company’s stock to trade at $7.00 in the next 52 weeks, with a low of $4.00 and a high of $12.00. (UBX) also has a 0.09 beta and a 0.17 average true range (ATR). The Relative Strength Index (RSI, 14) is now at 30.07, with a 7-day volatility ratio of 9.79 percent and a 30-day volatility ratio of 11.21 percent. UBX is now trading at a discount to its 20-day and 50-day simple moving averages of -23.53 percent and -39.80 percent, respectively. As a result, the stock’s average rating is Overweight, which may present an opportunity for investors looking to increase their holdings of the company’s shares. Meanwhile, 0 analyst(s) recommend Underweight and 0 recommend Sell. UBX has a Hold rating from 2 analysts, a Buy recommendation from 5 analysts, and an Overweight rating from 0 analysts. On a scale of 1.00 to 5.00, 7 analyst(s) have offered their prognosis ratings for the stock, ranging from a strong buy to a strong sell recommendation. On the other side, medium-term indications show that the stock is a 100 percent sell, while long-term indicators imply that the stock is a 100 percent sell. In terms of the stock’s technical picture, short term indications show that UBX is a 100 percent sell on average. Revisions may be used to provide insight into short-term price movement, and there have been no upward or downward revisions in the last seven days for the firm (s). According to the statistics, EPS growth is predicted to be 19.00% in 2021 and 12.10% the following year. ![]() Analysts expect the company’s earnings per share (EPS) to be -$0.38, with EPS expected to rise to -$1.49 in fiscal year 2021 and about -$1.31 in fiscal year 2022. is now around $74.09 million, with investors anticipating the company’s earnings release on Ma– March 25, 2022. The market capitalization of Unity Biotechnology Inc. We’ve set up an alert service to assist clever investors in taking full advantage of small-cap stocks that are poised for large gains. Over the last month, UBX has lost 37.50 percent of its value. In terms of its 52-week performance, the 52-week high and low were $9.78 and $1.31, respectively. Looking at the stock’s price trend, the stock closed at $1.36 in the most recent trading session, ranging in a range of $1.23 to $1.37. (NASDAQ:UBX) fell -4.41 percent from its previous day’s finish on Wednesday, December 29, as purchasers pulled the stock’s value down to $1.30. Unity Biotechnology Stock Price Target Forecast, (UBX) Prediction 2022, 2023, 2025, 2030Īt $1.30, Unity Biotechnology Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |